MILAN, Italy, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Dipharma Francis S.r.l. (Dipharma), a leading Contract Development and Manufacturing Organization (CDMO) and a global manufacturer of Active...
Dipharma Francis S.r.l., a global contract development and manufacturing organization (CDMO) and manufacturer of new chemical entities (NCE), generic active pharmaceutical ingredients and advanced intermediates, has completed the expansion of its research and development center for small molecules at its headquarters in Baranzate, Italy.
Dipharma Francis S.r.l., a global CDMO and manufacturer of Active Pharmaceutical Ingredients and advanced Intermediates, has completed the second phase of expansion of its American site, Dipharma Inc. in Kalamazoo, MI.
Dipharma completes second phase of CGMP expansion at its Kalamazoo site
Dipharma`s Sapropterin Receives Approval in the Europe
Dipharma Francis S.r.l.’s brand-new production line at the cGMP pilot plant suite, located in its facility of Mereto di Tomba (Italy), has been approved by the Italian Medicines Agency (AIFA).
MILAN--(BUSINESS WIRE)--Dipharma Francis S.r.l. (Dipharma), a leading Contract Development and Manufacturing Organization (CDMO) and a global manufacturer of Active Pharmaceutical Ingredients, announced today that the Italian Medicines Agency (AIFA) approved the brand-new production line at the cGMP pilot plant suite, located in its facility of Mereto di Tomba (Italy).
Dipharma B.V.'s Generic Sapropterin Hydrochloride Receives Approval in Europe
Dipharma S.A. (Dipharma), is a Swiss specialty pharmaceutical company, announced that its proprietary product Miglustat Dipharma 100 mg capsules is now available in Switzerland.